Best Sustainability Tech Companies in Vienna, Austria
The 72 best Sustainability Tech companies in Vienna, Austria in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: GROPYUS.
Our analysis of 293 Sustainability Tech companies
$38.4b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Sustainability Tech companies in Vienna
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GROPYUS Developer of green buildings | $251M | 3 mo ago | Series D | Bernd Oswald Co-Founder | 2019 | Wix eCommerceWixSentry+15 | 4 patents Robotic gripping and handling systems for wooden workpieces with integrated electrical fixation. | 1 expansion |
| 2 | Nabriva Developer of pleuromutilin class of antibiotics for MDR infections | $193M | 90 mo ago | Public | — | 2006 | DNNApple iCloud MailYouTube+16 | — | — |
| 3 | HOOKIPA Pharma Developer of immunotherapies for the treatment of infectious diseases and cancer | $134M | 30 mo ago | Public | — | 2011 | DrupalApple iCloud MailMicrosoft 365+19 | — | — |
| 4 | Themis Bioscience Prophylactic vaccines for infectious diseases | $83M | 81 mo ago | Acqui-Hired | — | 2009 | — | 60 patents Recombinant viral vaccine vectors and co‑stimulatory ectodomain proteins for immunomodulation | — |
| 5 | Intercell Developer of vaccines for infectious diseases (merged with Vivalis {France} to form Valneva in 2012) | $79M | 184 mo ago | Acquired | Arunabh Varma Founder & CEO | 1998 | — | 405 patents Vaccines and immunostimulatory oligodeoxynucleotide formulations targeting bacterial pathogens. | — |
| 6 | Enspired Alternative investment platform focused on trading energy assets | $36M | 25 mo ago | Series B | Mario Schmoltzi Co-Founder | 2020 | DrupalApple iCloud MailMicrosoft 365+24 | 4 patents Battery charge/discharge power management for energy storage systems | 1 partnership · 2 expansions |
| 7 | ecop Developer of industrial rotation heat pump technology for waste heat recovery | $23M | 12 mo ago | Series B | — | 2007 | WordPressMySQLPHP+18 | 10 patents Thermal energy conversion devices for waste heat recovery and heat‑to‑electric power. | 1 partnership |
| 8 | Arkeon Developer of protein ingredients through carbon-capture | $14M | 41 mo ago | Seed | Simon Rittmann Co-Founder | 2021 | — | 21 patents Amino acid production via methanogenic microorganisms in bioreactors | — |
| 9 | crystalsol Developer of flexible photovoltaic films | $11M | 69 mo ago | Series A | Thomas Badegruber Founder & CEO | 2008 | — | 15 patents Patents concentrated in electrical & electronics | — |
| 10 | HYDROGRID Intelligent IoT solution for optimizing and controlling hydropower plants | $8M | 30 mo ago | Series A | Janice Goodenough CEO | 2016 | WebflowFancyBoxcore-js+17 | — | — |
| 11 | Sequestra Platform that recycles industrial waste materials, enabling the reduction of global carbon emissions | $8M | 3 mo ago | Seed | Roberto Lerche Co-Founder | 2024 | Cart FunctionalitySquarespace CommerceSquarespace+18 | — | 1 expansion |
| 12 | Marinomed Developer of drugs for immunology, allergy and infectious diseases | $6M | 56 mo ago | Public | Eva Prieschl-Grassauer Co-Founder | 2006 | TYPO3 CMSPHPMicrosoft Advertising+7 | — | 1 launch · 1 partnership |
| 13 | EveliQure Biotechnologies Developing a vaccine against Diarrhea using a proprietary technology platform | $6M | 81 mo ago | Funding Raised | Gabor Somogyi CEO | 2012 | — | 35 patents High‑dose Shigella vaccine formulation and delivery technologies | — |
| 14 | EcoNetix Provider of carbon emission reduction solution | $5M | 9 mo ago | Seed | Jakob Zenz CEO and Founder | 2023 | WordPressMySQLPHP+35 | — | 3 partnerships · 1 award |
| 15 | PhagoMed Company developing alternatives to antibiotics through their expertise in phage therapy | $2M | 83 mo ago | Acquired | Burkhard Wippermann Co-Founder | 2016 | — | — | — |
| 16 | Wowflow SaaS-driven maintenance management software for owners and property managers | $1M | 46 mo ago | Seed | Misha Voronko Co-Founder | 2012 | — | — | — |
| 17 | Wohnio Provider of heating optimization solutions for residential and commercial properties | $1M | 9 mo ago | Seed | Kevin Bauer Founder & CEO | 2023 | Framer SitesYouTubeReact+7 | — | — |
| 18 | Ivary At-home diagnostic kits to assess the ovarian reserve | $1M | 111 mo ago | Deadpooled | Silvia Hecher Founder & CEO | 2014 | — | — | — |
| 19 | Grid Singularity Decentralized energy data exchange platform | $454K | 56 mo ago | Funding Raised | — | 2016 | — | — | — |
| 20 | imd Biotech Developer of diagnostic equipment for biomolecule detection and measurement | $431K | 25 mo ago | Seed | Peter Werzer Co-Founder | 2020 | — | — | 1 partnership · 2 awards |
| 21 | Carbon Recovery Provider of used tire recycling technology solutions | $380K | 95 mo ago | Seed | Christian Konvalina Managing Director | 2017 | — | — | — |
Top 12 Sustainability Tech companies in Vienna
#1
Series D · Vienna, Vienna · founded 2019 · 400 employees$251Mraised▾
Gropyus is a developer of green buildings. It uses timber-based materials in its buildings.
- Mar 2026Series D$118.1M
- Oct 2024Series C$109.7M
- Jan 2023Series B$108.8M
- Apr 2022Series A$32.5M
#2
Seed · Vienna, Vienna · founded 2024$8Mraised▾
Platform that recycles industrial waste materials, enabling the reduction of global carbon emissions. Its technology allows for carbonation of mineral materials,enabling the removal of carbon dioxide from the atmosphere.
- Mar 2026Seed$3.5M
- Mar 2026Grant (prize money)—
- Nov 2025Grant (prize money)$2.2M
- Sep 2025Grant (prize money)—
#3
Series B · Vienna, Vienna · founded 2007 · 11 employees$23.2Mraised▾
Developer of industrial rotation heat pump technology for waste heat recovery. It provides rotation heat pumps utilizing a patented technology for industrial applications. The heat pumps recover waste heat and efficiently elevate it to high temperatures for industrial processes, district heating, and cooling. The technology offers flexibility in applications such as heat boosting and combined heating/cooling processes.
- May 2025Series B$12M
- Jul 2024Grant (prize money)$9.2M
- Aug 2018Grant (prize money)$2M
#4
Seed · Vienna, Vienna · founded 2023$5.3Mraised▾
Provider of carbon emission reduction solution. It measures and reports carbon emissions digitally by implementing IoT system that uses sensors, satellite imaging, weather data, and AI algorithms.
- Sep 2025Seed$5.3M
- Mar 2024Seed—
#5
Seed · Vienna, Vienna · founded 2023$1.3Mraised▾
Provider of heating optimization solutions for residential and commercial properties. The company offers services to digitize and decarbonize heating systems. It facilitates the transition to green energy systems. The company provides portfolio oversight, continuous optimization, and early detection of system defects.
- Sep 2025Seed$939.3K
- Feb 2025Seed$359.2K
#6
Public · Vienna, Vienna · founded 2011 · 132 employees$133.7Mraised▾
Developer of immunotherapies for the treatment of infectious diseases and cancer. The company uses a proprietary arenavirus platform to develop a product pipeline that inlcudes HB-201 and HB-202 for the treatment of Human Papillomavirus-16 positive (HPV16+) cancers.
- Dec 2023Post IPO$21.2M
- Feb 2019Series D$37.4M
- Dec 2017Series C$59.6M
- Oct 2016Grant (prize money)$4.6M
#7
Series B · Vienna, Vienna · founded 2020 · 59 employees$36.2Mraised▾
Alternative investment platform focused on trading energy assets. It provides AI-driven solutions to optimize power portfolio. It provides solutions to direct market access with power trading services based on data, self-learning models, and cutting-edge technology.
- May 2024Series B$27.5M
- Dec 2021Series A$8.7M
#8
Public · Vienna, Vienna · founded 2006 · 39 employees$193.1Mraised▾
Nabriva Therapeutics is developing pleuromutilin class of antibiotics for MDR infections. Its lead product candidate is Lefamulin for treating acute bacterial skin and skin structure infections (phase II); intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP) (FDA approved); for pediatric indications (phase I), STI, osteomyelitis, HABP/VABP, and prosthetic joined infections (phase I). The antibiotic binds to a specific site on the bacterial ribosome responsible for bacterial protein synthesis. It has also developed Contepo (IV) for treating cUTI (NDA/MAA filing) and pediatric indications (phase I).
- Dec 2018Conventional Debt$25M
- Jul 2018Post IPO$21.3M
- Apr 2015Series B$120M
- Oct 2009PE$22.3M
#9
Acqui-Hired · Vienna, Vienna · founded 2009 · 40 employees$82.5Mraised▾
Themis Bioscience is focussed on developing prophylactic vaccines for infectious diseases. It is using its proprietary Themaxyn platform to identify and advance its vaccine candidates at various stages of development. It has initial vaccine candidates currently in development for chikungunya and dengue fever. The company has developed cancer therapies using a measles vector, such as adding different tumour killing and immune-modulatory payloads to increase the oncolytic effect.
- Sep 2019Series D$44.1M
- Jun 2019Grant (prize money)—
- Jan 2018Series C$12M
- Nov 2016Series B$10.6M
#10
Series A · Vienna, Vienna · founded 2016$8.5Mraised▾
Intelligent IoT solution for optimizing and controlling hydropower plants.The solution include real time predictive production planning, monitoring, and decision support tools for hydropower plant operators and traders. The software integrates machine learning algorithms to enable hydropower operators to react in real time to weather events, minimize water losses, and maximize power market revenues.
- Dec 2023Series A$8.5M
#11
Seed · Vienna, Vienna · founded 2021 · 35 employees$13.8Mraised▾
Developer of protein ingredients through carbon capture. The technique is carbon-negative, independent of agricultural land, and employs industrial CO₂ as a feedstock. It provides a sustainable alternative to traditional protein synthesis.
- Jan 2023Seed$3M
- Dec 2022Seed$4.2M
- Mar 2022Seed$6.5M
#12
Acquired · Vienna, Vienna · founded 1998$78.6Mraised▾
Intercell was developing vaccines for infectious diseases. It developed antigens and adjuvants for vaccines. In Dec 2012, Vivalis acquired Intercell for $174M, and the combined entity was renamed Valneva. The company had a vaccine for Japanese encephalitis in the market at the time of its acquisition.
- Feb 2011Series B$45M
- Jul 2003Series A$33.6M
Funding & investor landscape
Amazon Web Services2 roundsNotable founders
Market landscape — 10 sub-themes by coverage
Share of Sustainability Tech coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
What Vienna researches in climate adaptation
- Vienna University of Economics and Business7
- University of Vienna7
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.